Emergent Biosolutions (EBS) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/09/23
Emergent Biosolutions (EBS) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 05/02/23
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023GlobeNewsWire • 04/19/23
Emergent Biosolutions (EBS) Surges 5.1%: Is This an Indication of Further Gains?Zacks Investment Research • 03/30/23
Emergent Biosciences (EBS) Stock Pops as FDA Approves Over-the-Counter NarcanInvestorPlace • 03/29/23
U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions' NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency TreatmentGlobeNewsWire • 03/29/23
FDA approves over-the-counter sales of lifesaving opioid overdose treatment Narcan nasal sprayCNBC • 03/29/23
Wall Street Analysts Believe Emergent Biosolutions (EBS) Could Rally 134.29%: Here's is How to TradeZacks Investment Research • 02/28/23
Analysts Estimate Emergent Biosolutions (EBS) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 02/20/23
Emergent BioSolutions: Positive NARCAN FDA Panel, Divesting Travel Health, Raising Rating To BuySeeking Alpha • 02/19/23
Emergent's stock jumps after FDA panel favors over-the-counter sales of NarcanMarket Watch • 02/16/23
Emergent Biosolutions (EBS) Moves 12.5% Higher: Will This Strength Last?Zacks Investment Research • 02/16/23
Emergent BioSolutions Reports FDA Advisory Committees' Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter UseGlobeNewsWire • 02/15/23